title: Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy.
abstract: Rituximab, a chimeric monoclonal CD20 antibody, is useful in the treatment of B-cell lymphomas and certain autoimmune diseases. We report a successful outcome of rituximab for life threatening hypercoagulable state associated with lupus anticoagulant (LA). A 30-year-old woman initially presented 10 years ago with DVT and positive serology for SLE and LA. While on Coumadin, she suffered from recurrent DVT in the legs and arms, pulmonary emboli, Budd-Chiari syndrome, mesenteric vein thrombosis, bone infarcts, recurrent strokes, and chronic ITP. All measures including plasmapheresis and monthly IV cyclophosphamide were of no benefit. She was recently admitted with spontaneous subdural hematoma with INR of 3.8. Upon discontinuation of anticoagulation for surgical drainage, she developed acute abdomen from thrombosis and recurrent DVT. Because she had failed prior standard measures, 4 weekly infusions of rituximab (375 mg/m2) were given following 2 rounds of plasmapheresis. Subsequently, she made a remarkable recovery over the next month and has been free of thrombosis on Coumadin for over 15 months. LA, IgM antibodies to cardiolipin, and B2GP1 were consistently positive. After rituximab therapy, LA became negative and IgM antibodies to cardiolipin decreased and ITP went into remission. Rituximab induced a lasting remission in a woman suffering from life-threatening hypercoagulable state associated with LA. Her clinical remission was associated with disappearance of LA.
authors.affiliation: Department of Microbiology/Immunology, University of Miami School of Medicine, Miami, FL 33136, USA. eahn@med.miami.edu
authors.forename: Eugene R
authors.initials: ER
authors.lastname: Ahn
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lander
authors.forename: Carlos J
authors.initials: CJ
authors.lastname: Bidot
authors.forename: Wenche
authors.initials: W
authors.lastname: Jy
authors.forename: Yeon S
authors.initials: YS
authors.lastname: Ahn
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000187:drug effects; D016638:Critical Illness; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000187:drug effects* / Q000502:physiology; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D017211:Treatment Failure; D014652:Vascular Diseases / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D014859:Warfarin
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D016682:Lupus Coagulation Inhibitor; D000069283:Rituximab; D014859:Warfarin